X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.
Lead Product(s): Brolucizumab
Therapeutic Area: Ophthalmology Product Name: Beovu
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $8.0 million Upfront Cash: $8.0 million
Deal Type: Agreement March 27, 2024
Details:
The net proceeds will be used in the clinical development of the company’s lead antibody-drug conjugate therapeutic candidate PYX-201, which is currently evaluated in the clinical trial studies for patients with relapsed/refractory solid tumors.
Lead Product(s): PYX-201
Therapeutic Area: Oncology Product Name: PYX-201
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Deep Track Capital
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 27, 2024
Details:
Through the acquisition, Pyxis Oncology positions at forefront of Antibody-Drug Conjugate (ADC) development by adding PYX-107 (sotigalimab), a potential best-in-class Phase 2 CD40 agonist in clinical development for liposarcoma, melanoma, and other cancers.
Lead Product(s): Sotigalimab
Therapeutic Area: Oncology Product Name: PYX-107
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Apexigen
Deal Size: $10.7 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 23, 2023
Details:
PYX-106 is a fully human immunotherapy antibody candidate in development that blocks the activity of Siglec-15, it is an emerging immune suppressor expressed across a broad range of solid tumors.
Lead Product(s): PYX-106
Therapeutic Area: Oncology Product Name: PYX-106
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
Through the acquisition, Pyxis Oncology positions at forefront of Antibody-Drug Conjugate (ADC) development by adding APX 005 (sotigalimab), a potential best-in-class Phase 2 CD40 agonist in clinical development for liposarcoma, melanoma, and other cancers.
Lead Product(s): Sotigalimab
Therapeutic Area: Oncology Product Name: APX 005
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pyxis Oncology
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition May 24, 2023
Details:
The gross proceeds will be used to finance and further support the company’s ongoing Phase 2 clinical study evaluating its CD40 antibody, APX005M (sotigalimab), in combination with doxorubicin in patients with liposarcoma.
Lead Product(s): Sotigalimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Brookline Capital Markets
Deal Size: $2.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 24, 2023
Details:
Sotiga (sotigalimab) is a humanized monoclonal antibody that binds CD40 with high affinity and activates antigen presenting cells (dendritic cells, monocytes and B cells) leading to stimulation of cancer-specific T-cell responses leading tumor-specific immune activation.
Lead Product(s): Sotigalimab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Sotiga
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
APX005M (sotigalimab) is a CD40 agonist that has been designed to reverse the systemic immune suppression that typically affects cancer patients, through the activation of several mechanisms of immune functionality.
Lead Product(s): Sotigalimab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: APX005M
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2022
Details:
The combination of intratumoral sotigalimab and systemic pembrolizumab was well-tolerated and demonstrated an improved clinical response rate relative to the standard of care, pembrolizumab monotherapy.
Lead Product(s): Sotigalimab,Pembrolizumab
Therapeutic Area: Oncology Product Name: Sotiga
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Sotiga (sotigalimab) in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in patients with both adenocarcinoma and squamous cell carcinoma.
Lead Product(s): Sotigalimab,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: Sotiga
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
